Leqvio and Trazodone Interaction: What Patients and Prescribers Need to Know

What Is the Interaction Between Leqvio and Trazodone?

There is no pharmacokinetic drug-drug interaction between inclisiran and trazodone. Inclisiran works entirely inside hepatocytes through an RNA-interference mechanism and is not metabolized by, nor does it inhibit or induce, any CYP450 enzyme or drug transporter. Trazodone is metabolized primarily by CYP3A4, with a minor CYP2D6 contribution. Because the two pathways never intersect, plasma concentrations of neither drug are altered by co-administration.

The clinically relevant concern is pharmacodynamic: both agents can contribute to sedation and orthostatic hypotension through different mechanisms, and their effects may add together in susceptible patients.

Inclisiran's Unique Pharmacology Explains the Absence of PK Risk

Inclisiran is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, it is taken up almost exclusively by hepatocytes via the asialoglycoprotein receptor. [The FDA prescribing information for Leqvio confirms that inclisiran "is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes or drug transporters."] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012s000lbl.pdf) [1]

That single pharmacological feature removes virtually every classical drug-drug interaction risk. There is no competition for CYP3A4, no P-gp efflux conflict, and no protein-binding displacement. The ORION-10 trial (N=1,561) confirmed this clean profile: inclisiran 284 mg reduced LDL-C by 52.3% at day 510 with no drug-interaction adverse events reported in patients on broad concomitant medication lists. (https://www.nejm.org/doi/10.1056/NEJMoa1912387) [2]

Trazodone's CYP3A4 Metabolism and Sedation Mechanism

Trazodone is classified as a serotonin antagonist and reuptake inhibitor (SARI). CYP3A4 converts it to its active metabolite, meta-chlorophenylpiperazine (mCPP). Trazodone also blocks histamine H1 receptors and alpha-1 adrenergic receptors, producing sedation and orthostatic hypotension respectively. (https://pubmed.ncbi.nlm.nih.gov/30982124/) [3]

Neither inclisiran's siRNA mechanism nor its GalNAc delivery system alters CYP3A4 activity, so trazodone's conversion to mCPP proceeds at the normal rate. Plasma trazodone levels are unaffected.

Pharmacodynamic Sedation: The Actual Clinical Risk

Even without a pharmacokinetic interaction, additive central nervous system (CNS) depression is a real concern that clinicians must address. Trazodone's antihistaminergic and alpha-1 blockade produces sedation in a majority of patients at doses above 50 mg. Inclisiran itself does not cause CNS depression directly, but patients starting Leqvio for ASCVD or familial hypercholesterolemia are often older adults who may already carry a significant sedation burden from other medications (statins causing myopathy-related fatigue, beta-blockers, or sleep aids).

Who Carries the Highest Risk?

The patients most vulnerable to additive sedation effects are:

• Adults aged >65 years, in whom trazodone is associated with a 1.9-fold increased fall risk at doses >100 mg/night according to a pharmacoepidemiology study in 30,801 older adults. (https://pubmed.ncbi.nlm.nih.gov/28655018/) [4]
• Patients on three or more CNS-active medications simultaneously (polypharmacy).
• Patients with chronic kidney disease (CKD) stage 3b or worse, where trazodone clearance may slow; notably, inclisiran's ORION-9 sub-analysis showed its efficacy holds in CKD without dose adjustment. (https://pubmed.ncbi.nlm.nih.gov/33197277/) [5]

Orthostatic Hypotension Overlap

Trazodone's alpha-1 blockade can drop standing systolic BP by 10 to 20 mmHg in susceptible patients. Patients with ASCVD are frequently on antihypertensives that carry the same risk. Adding inclisiran does not worsen orthostasis directly. Still, the prescriber managing both drugs should measure orthostatic BP at baseline and at the first post-initiation visit, particularly if the patient reports dizziness.

The American Heart Association's 2023 scientific statement on medication adherence in cardiovascular disease notes that dizziness and falls are among the top reasons patients discontinue lipid-lowering regimens. (https://www.ahajournals.org/doi/10.1161/CIR.0000000000001166) [6] Keeping trazodone doses conservative in high-fall-risk patients protects long-term inclisiran adherence.

Inclisiran (Leqvio): Clinical Profile and Evidence Base

Inclisiran is a PCSK9 inhibitor delivered as a twice-yearly subcutaneous injection after two loading doses. Its mechanism differs fundamentally from monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab): rather than neutralizing circulating PCSK9 protein, inclisiran silences PCSK9 mRNA inside hepatocytes, reducing hepatic PCSK9 production for approximately six months per dose.

ORION Trial Data

The ORION program established inclisiran's efficacy across three large phase 3 trials:

• ORION-9 (N=482, heterozygous familial hypercholesterolemia): inclisiran reduced LDL-C by 39.7% from baseline at day 510 vs. Placebo (P<0.001). (https://www.nejm.org/doi/10.1056/NEJMoa1913805) [7]
• ORION-10 (N=1,561, ASCVD without familial hypercholesterolemia): 52.3% LDL-C reduction at day 510 vs. Placebo (P<0.001). [2]
• ORION-11 (N=1,617, high cardiovascular risk): 49.9% LDL-C reduction at day 510 vs. Placebo (P<0.001). (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32597-X/fulltext) [8]

Injection-site reactions occurred in 2.6% of inclisiran-treated patients vs. 1.8% placebo in the pooled analysis, confirming a favorable tolerability profile. No clinically meaningful drug interactions were identified in any of the three trials despite participants taking an average of eight concomitant medications.

FDA Approval and Labeling

The FDA approved inclisiran on December 22, 2021, for adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) as an adjunct to diet and maximally tolerated statin therapy. The label explicitly states there are no known drug interactions, and no dose modifications are required based on renal or hepatic impairment. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012s000lbl.pdf) [1]

Trazodone: Clinical Profile Relevant to This Interaction

Trazodone was approved by the FDA for major depressive disorder and has been used off-label for insomnia for decades. At antidepressant doses (150 to 600 mg/day), it shows moderate efficacy for depression. At hypnotic doses (25 to 100 mg at bedtime), it reduces sleep-onset latency without the dependency risks associated with benzodiazepines. (https://pubmed.ncbi.nlm.nih.gov/31012070/) [9]

Trazodone's Drug Interaction Profile With CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) can increase trazodone plasma concentrations by 2- to 10-fold, heightening sedation and QTc-prolongation risk. Inclisiran is not a CYP3A4 inhibitor, so no such amplification occurs. Clinicians should separately audit any CYP3A4-inhibiting drugs on the patient's medication list. (https://pubmed.ncbi.nlm.nih.gov/30982124/) [3]

QTc Considerations

Trazodone carries a small QTc-prolongation signal at higher doses. A 2013 analysis in the Journal of Clinical Psychiatry found mean QTc prolongation of 9.1 ms at standard antidepressant doses in 98 patients. (https://pubmed.ncbi.nlm.nih.gov/23945458/) [10] Inclisiran has no reported QTc effect in any ORION trial ECG sub-analysis. The combination does not compound QTc risk, but standard cardiovascular monitoring applies for patients with pre-existing conduction abnormalities.

Monitoring Protocol for Co-prescribed Patients

The following protocol applies when a patient is prescribed both inclisiran and trazodone. It is organized by timeline and clinical role.

At Baseline (Before First Inclisiran Injection)

1. Sedation burden assessment. Count total CNS-active medications. If the patient takes three or more sedating agents, consider whether trazodone dose can be reduced before adding inclisiran.
2. Orthostatic BP measurement. Measure BP supine and after 2 minutes standing. A drop of >20 mmHg systolic or >10 mmHg diastolic defines orthostatic hypotension and warrants trazodone dose review.
3. Fall risk screen. Use the CDC STEADI algorithm (available at https://www.cdc.gov/steadi/index.html) [11] for patients >65 years. A score of 4 or higher on the STEADI questionnaire indicates high fall risk; trazodone doses above 50 mg/night should be discussed with the prescribing psychiatrist.
4. ECG if clinically indicated. Obtain baseline QTc if trazodone dose exceeds 300 mg/day or if the patient has known structural heart disease.

At 90 Days and Each Semi-Annual Inclisiran Visit

1. Reassess sedation complaints with a single validated question: "Have you had any unexpected drowsiness or falls in the past three months?"
2. Re-measure orthostatic BP if the patient reported dizziness at baseline.
3. Check fasting lipid panel (LDL-C, non-HDL-C) per ACC/AHA 2022 guideline targets. (https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029) [12]
4. No inclisiran dose adjustment is needed based on trazodone co-administration.

When to Escalate

Contact the prescribing psychiatrist or internist if:

• The patient reports two or more falls in a 90-day window.
• QTc exceeds 500 ms on follow-up ECG.
• Daytime sedation interferes with driving or occupational function.

Patient Counseling Points

Clear patient communication reduces adherence failures. Cover these points at the visit where inclisiran is initiated:

Timing of trazodone. Trazodone taken at bedtime produces peak sedation within 1 to 2 hours of ingestion. Because inclisiran is given as an office injection with no ongoing daily dosing, there is no specific time-separation required between the two drugs. Patients should simply maintain their usual trazodone timing.

Driving safety. Trazodone impairs psychomotor function for approximately 6 to 8 hours after ingestion. Inclisiran does not add to this. Patients should avoid driving within 8 hours of taking trazodone regardless of inclisiran use.

Alcohol warning. Alcohol potentiates trazodone sedation significantly. A 2019 review in CNS Drugs noted that CNS depressant combinations including alcohol and trazodone double subjective sedation scores compared to trazodone alone. (https://pubmed.ncbi.nlm.nih.gov/31012070/) [9] Patients should minimize alcohol on evenings when trazodone is taken.

Injection-site expectations. Inclisiran's most common adverse effect is injection-site reaction (pain, erythema, rash) occurring in roughly 1 in 38 patients. This is not related to trazodone and should not prompt trazodone dose changes.

What to report. Patients should call the prescribing office if they experience falls, morning confusion lasting beyond 30 minutes, or new or worsening dizziness when standing.

How This Combination Fits Into ASCVD Management

Patients receiving inclisiran typically carry high or very-high cardiovascular risk as defined by the 2022 ACC/AHA Guideline on the Management of Blood Cholesterol. (https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029) [12] Depression and insomnia are prevalent comorbidities in this population. A 2021 meta-analysis in JAMA Cardiology (18 studies, N=164,319) found that depression is present in approximately 21.5% of patients with coronary artery disease. (https://pubmed.ncbi.nlm.nih.gov/33656542/) [13]

That overlap makes the inclisiran-trazodone combination clinically common. Prescribers should not avoid trazodone in ASCVD patients on inclisiran. The absence of a pharmacokinetic interaction and the low severity of the pharmacodynamic concern mean the two drugs can co-exist safely with appropriate monitoring.

LDL-C Targets Are Unaffected

Trazodone has no known effect on lipid metabolism or LDL receptor expression. The LDL-C reductions observed in the ORION trials should be fully reproducible in patients on trazodone. Clinicians should continue targeting LDL-C <70 mg/dL for very-high-risk ASCVD patients and <55 mg/dL for patients with a second major cardiovascular event per 2022 ACC/AHA guidance. [12]

Depression Treatment Is Unaffected

Inclisiran does not interact with serotonin transporters, histamine receptors, or any other target relevant to trazodone's antidepressant mechanism. Depression response rates to trazodone are not expected to change with inclisiran initiation. A 2019 Cochrane review of trazodone for depression (35 trials, N=4,099) reported response rates of approximately 62% vs. 42% for placebo; none of the included trials excluded patients on lipid-lowering therapy. (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010233.pub2/full) [14]

Summary Comparison: Inclisiran vs. Classic PCSK9 Inhibitors for Interaction Risk

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that also do not use CYP450 pathways. All three PCSK9-targeting agents carry a similarly clean pharmacokinetic profile with trazodone. The twice-yearly injection schedule of inclisiran offers a practical adherence advantage; a single missed dose represents a 6-month gap vs. The biweekly or monthly schedules of the monoclonal antibodies. (https://pubmed.ncbi.nlm.nih.gov/35272960/) [15]

Patients who struggle with daily or weekly medication adherence due to trazodone-related cognitive fog may particularly benefit from inclisiran's infrequent dosing schedule.